Jane Street
OLMA icon

Jane Street’s Olema Pharmaceuticals OLMA Stock Holding History

Jane Street’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$599K Sell
40,200
-3,000
-7% -$66.8K ﹤0.01% 7624
2025
Q4 		$1.08M Buy
+43,200
New +$769K ﹤0.01% 5964

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Jane Street's OLMA Position: Q2 2025 in Review

Jane Street sold out of Olema Pharmaceuticals (OLMA) in Q2 2025, closing a stake of 138,552 shares — an estimated $521K sold.

Jane Street first reported a position in OLMA in Q4 2021 and held it in 10 quarters. The position peaked at $570K in Q2 2024. 122 funds tracked by Wall St. Rank hold OLMA as of Q2 2025.

  • Jane Street reported no remaining Olema Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Jane Street sold 138,552 Olema Pharmaceuticals shares in Q2 2025, an estimated $521K.
  • Jane Street first reported a position in Olema Pharmaceuticals in Q4 2021 and held it in 10 quarters.
  • Jane Street's Olema Pharmaceuticals position peaked at $570K in Q2 2024.
  • 122 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2025.

Based on Jane Street's 13F filing for Q2 2025, filed 14 Aug 2025.